key: cord-0798774-1kpa6jwe
authors: Göpel, Siri; Bethge, Wolfgang; Martus, Peter; Kreth, Florian; Iftner, Thomas; Joos, Stefanie; Döbele, Stefanie; Mordmüller, Benjamin; Kremsner, Peter; Ettrich, Thomas; Seufferlein, Thomas; Bitzer, Michael; Malek, Nisar
title: Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial
date: 2020-07-10
journal: Trials
DOI: 10.1186/s13063-020-04556-z
sha: f99c1a002a1f7c3b0f9e846319cc8be1ac18cf3c
doc_id: 798774
cord_uid: 1kpa6jwe

OBJECTIVES: The aim of this trial is to identify the effect of ambulatory treatment in early COVID-19 disease with hydroxychloroquine on the rate of hospitalization or death in older patients above the age of 64. TRIAL DESIGN: Parallel, 2:1 randomization, double blind, placebo-controlled, multi-center trial. PARTICIPANTS: Male and female patients above the age of 64 (i.e. ≥65 years of age) with COVID-19 diagnosis confirmed by SARS-CoV2 positive throat swab (PCR). Patients can only be included within 3 days of symptom onset in ambulatory care if they consent to the study procedure and are able to adhere to the study visit schedule and protocol requirements (including telephone visits concerning symptoms and side effects). Severity of disease at inclusion is mild to moderate defined as not requiring hospital admission: SpO2 >94%, respiratory rate <20, mental state alert, no signs of septic shock. Cardiac risk is minimised by requiring a Tisdale score ≤ 6. Patients are recruited in the two german cities of Ulm and Tübingen in various ambulatory care settings. INTERVENTION AND COMPARATOR: Each patient will be given a first dose of 600 mg Hydroxychloroquine or the equivalent number of placebo capsules (3 capsules) at the day of inclusion. From the 2(nd) day on, each patient will get 200 mg or the equivalent number of placebo capsules twice a day (400mg/day) until day 7 (6 more does of 400 mg); a cumulative dose of 3 g. MAIN OUTCOMES: Rate of hospitalization or death at day 7 after study inclusion RANDOMISATION: All consenting adult patients having confirmed COVID-19 are randomly and blindly allocated in a 2:1 ratio to either IMP or placebo. The biostatistical center produced a randomization list (block randomization) with varying block length and stratified for the study center. This list is provided for packaging to the pharmaceutical unit which is providing encapsulated placebo and IMP. Only the pharmaceutical unit is aware of group allocation according to the randomization list. BLINDING (MASKING): Patients and investigators, as well as treating physicians are blinded to the treatment- allocation. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): In the first stage of an adaptive design 120 patients in a 2:1 ration: 72 Verum and 36 Placebo, plus an increase for 10% drop outs. After interim analysis, the total sample size will be calculated based on the effect seen in the first stage. Total sample size is estimated approximately n = 300-400 patients. TRIAL STATUS: Protocol version number: V3, 19.05.2020 Recruitment not yet started but is anticipated to begin by June 2020 and be complete by December 2020 TRIAL REGISTRATION: ClinicalTrials.gov: NCT04351516, date: 17 April 2020 EudraCT: 2020-001482-37, date: 30 March 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

II. 

This is national study with 2 or more sites in Germany

In the face of the pandemic spread of COVID19, health care systems are facing major challenges due to large amounts of patients requiring hospital care and intensive medicine care. As soon as the capacities of the individual health care system are surpassed, optimized care for all cannot be guaranteed any more. Containment strategies in Germany include quarantine of infected persons and quarantine of contact persons for 14 days (incubation period). On a population level reduction of contacts has been pursued by most affected countries with various measures such as closure of schools, shops, gastronomy and in the extreme a total lockdown. Fatality and severe courses of the disease are more common in the older population above the age of 60 years (WHO 2020). 30% of patients in Wuhan were in the age group from 60 to >80 years, but 80% of the fatalities occurred in these age groups (CCDC 2020) Outbreaks in longterm care facilities have been observed in several countries, posing specific challenges in containment and isolation within the facility, thereby affecting and threatening the most vulnerable. Lack of personal protective equipment enhances the problem.

Treatment options include best supportive care and management of ARDS and sepsis (WHO 01/2020). A large scale of potential antiviral drug candidates has been defined partly by molecular analyses, partly by in vitro testing or known effects against structural similar MERS and SARS (Guangdi Li et al 2020).

In vitro data show that hydroxychloroquine can inhibit SARS-CoV-2 replication (Wang et.al 2020) and preliminary results from small numbers of COVID-19 patients in China and France (Gao et al. 2020 and Gautret et al. 2020) suggest that chloroquine enhances viral clearance. Published literature until now reports mainly non-controlled use of the medication in hospitalized patients. Median time from onset of symptoms to hospitalization in a large Chinese cohort was 7 days (CCDC 2020), so it can be hypothesized that treatment is delayed substantially especially in the population most at risk for severe course of disease if treatment is only implemented in hospitalized patients.

We propose to conduct a placebo-controlled trial in elderly COVID-19 patients with mild to moderate disease in an outpatient setting in Germany to assess the effect of hydroxychloroquine treatment on the rate of hospitalization. Secondary endpoints will explore time to hospital admission, safety and tolerability of hydroxychloroquine, clinical outcome including rate of ICU admission, rate of mechanical ventilation and viral clearance in vivo as well as longterm mortality of all causes after 60 days. Many other drugs are under investigation for repurposing them in the treatment of COVID19. This trial will set up a structure to investigate hydroxychloroquine versus placebo as the now most promising candidate.

Chloroquine or Hydroxychloroquine are widely prescribed drugs for the treatment and prophylaxis of malaria or autoimmune disease. They have a known safety profile, which allows their use under known precautions in a large population. Use in the above mentioned indications is usually done over several months (Michalski et al. 2010 ).

In vitro results revealed several mechanisms that promote the use of Chloroquine and Hydroxychloroquine in Sars-CoV2-Infection: Zhou et al. (2020) demonstrated that SARS-CoV-2 uses angiotensin converting enzyme 2 receptor (ACE2) as a cellular entry receptor.

Especially in this cellular entry mechanism, Sars-CoV2 has strong structural homologies to SARS-CoV (Xu et al. 2020) which has already been studied for several years. Vincent et al (2005) showed that Hydroxychloroquine blocks the terminal glycosylation of the receptor, resulting in inhibition of SARS-CoV infection and it affects the activation of p38 mitogenactivated protein kinase (MAPK), involved in the replication of HCoV-229E (Kono et.al. 2008) .

Furthermore, Hydroxychloroquine increases the endosomal pH, thus inhibiting infection through SARS-CoV2 since virus to cell fusion requires a low endosomal pH . In vitro, Hydroxychloqoruine was able to block viral replication at an EC of 1.1µM (Wang et al.2020) Several clinical trials have been initiated and are currently being conducted to confirm in vivo efficacy of Hydroxychloroquine or Chloroquine. Gao et al (2020) reported superiority of Chloroquine compared to Placebo in more than 100 patients both in terms of clinical outcome and reduction of viral load.

Chinese expert consensus recommend that patients diagnosed as mild, moderate and severe cases of COVID-19 pneumonia and without contraindications to chloroquine, be treated with 500 mg chloroquine twice a day for ten days. However, until now the above mentioned study has not been published, reporting is limited to a short abstract.

Following these findings, a open-label, non-randomized clinical trial was conducted in France by Gautret et al (March 2020 ) on a small cohort of 36 COVID19 patients. Treatment was Hydroxychloroquine 3x200mg/ day for 10 days. They showed a significant effect on viral clearance in the treatment group (20 Patients) compared to non-treatment group (16 Patients) at day 6.

Many clinical trials are ongoing in several countries (China, France, USA, Germany) using chloroquine or hydroxychloroquine for the treatment of COVID19 disease caused by SARS-CoV2. These studies have focused on the treatment of hospitalized patients. In other studies median time from symptom onset to hospitalization was 7 days , thus potential treatment might be delayed in a considerable amount of patients. Early diagnosis by testing in an early stage of disease and early intervention by effective drugs might alter the course of the disease especially in the population most at risk for severe course of disease. In a population-based approach, altering the course of disease in this population most at risk can prevent hospital admissions and intensive care thus alleviating the pressure on the healthcare system.

In the proposed study patients will be randomized in a 2:1 ratio to either hydroxychloroquine or placebo. Patients and investigators, as well as treating physicians will be blinded to treatmentallocation.

COVID-19 constitutes a severe threat to public health as no treatment or preventive medical intervention is available. In patients suffering from severe COVID-19 only supportive care and treatment of complication is available. Prevention is only feasible by social distancing and isolation of positive patients. Screening of known drugs with antiviral properties has revealed possible candidates on a molecular level and in vitro results have further enhanced possible treatment options. The last data released by Gautret et al. in March 2020 showed a small cohort of 36 COVID19 patients. Treatment was Hydroxychloroquine 3x200mg/day for 10 days. They showed a significant effect on viral clearance in the treatment group (20 Patients) compared to non-treatment group (16 Patients) at day 6. Mean Hydroxychloroquine concentration was 46µg/ml (N20).

In this study, hydroxychloroquine will be assessed against placebo in a specific at risk population at a very early stage of disease. HCQ will be used since in vitro and in vivo studies show it to be better tolerated and have higher anti-SARS-CoV-2activities in in vitro assays (Xuetin Yao et al 2020) .

In some countries, the above mentioned candidate drugs (including Hydroxychloroquine) are already being used in clinical treatment, however, data of randomized clinical controlled trials are scarce. This caused the EMA to issue a warning of the use of Hydroxychloroquine outside controlled clinical trials at the end of March 2020 and the WHO highly encouraged conducting controlled clinical trials. As for now, the optimal dosing regimen in the context of COVID19 remains unclear. Existing study protocols use dosages ranging from 200mg/day to 600mg/day, some of them initiated with a slightly higher loading dose (CDC 03/2020).

A recent study (Yao X et al 2020) compares achievable plasma levels and estimated lung trough concentrations in different dosing regimens with the in vitro activity of hydroxychloroquine against SARS-CoV2 and proposes a regimen with 800mg loading dose followed by 5 days 400mg/day. However, these data rely on plasma level estimations from patients ranging from 20-50years and are not correlated to clinical outcome.

Based on these results we propose for patients over 64 years a reduced loading dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days resulting in a total duration of therapy of 7 days. Measurement of Hydroxychloroquine-levels will be performed on day 7, the blood sample being collected and frozen at -20°C to avoid unblinding.

Associated risks are mostly related to toxicity of HCQ. In the above mentioned dosing scheme, a cumulative dose of 3 g will be taken. At this dose, gastrointestinal symptoms, headaches, sight problems and psychological symptoms are common (≥1/100). Described serious adverse events include retinopathy (particularly with cumulative dosed >200g), hypoglycaemia, QT-interval prolongation, cardiomyopathy, neurological and psychological syndromes.

Hydroxychloroquine has been used as a longterm treatment in several rheumatological disorders and shortterm treatment of Malaria in doses similar to the above mentioned with known sideeffects and known riskfactors. This allows a safe usage under known precautions:

Exclusion criteria of the study protocoll reflect known side effects and interactions of Hydroxychloroquine and thus allow the usage with minimized risk.

On the other hand fatality and severe courses of COVID19-disease are more common in the older population above the age of 60 years (WHO 2020). 30% of patients in Wuhan were in the age group from 60 to >80 years, but 80% of the fatalities occurred in these age groups (CCDC 2020). Hence an effective antiviral therapy wold be highly beneficial especially to the population included in the study.

In this trial, testing and study inclusion will be done in the outpatient setting. A followup by video or telephone conference will be performed to observe drug intake and collect adverse events during treatment phase on a daily base on working days and once during the weekend (i.e. 6 out of 7 days). After treatment phase follow-up by telephone calls will be done on day 10, 30, 60 (+/-2 days). Additionally an App will be offered to patients to document their symptoms in a standardized way in terms of a symptom diary. ECG and blood sampling will be done prior to randomisation to allow exclusion of patients at special risks. After seven days patients clinical status will be assessed at the study center including physical examination, blood sample, ECG and a second throat swab. If feasible throat swabs will be also collected on day 14 and 21.

Data and Safety Monitoring Board (DSMB): An independent Data and Safety Monitoring Board (DSMB) will be assembled. The DSMB will be composed of independent experts in the field of infectious diseases and an independent statistician, assessing the progress, safety data and critical efficacy endpoints. The mission of the DSMB will be to ensure the ethical conduct of the trial and to protect the safety interests of patients in this trial. The DSMB will receive a report listing summarizing all the relevant safety data every two weeks from the inclusion of the first patient, after the inclusion of 20 patients in the verum group a safety analysis will be performed not embedded in the framework of the adaptive design according to Bauer and Köhne (1994) .The analysis will be provided to the DSMB. The DSMB will provide the sponsor with recommendations regarding trial modification, continuation or termination of the trial. The DSMB will then be informed every 30 days. After treatment of 36 Placebo und 72 Verum Patients (+ increase for 10% drop outs = 120 patients in total) the primary endpoint will be analysed. The outcome will be discussed with the DSMB. The members of the DSMB, their responsibilities as well as the frequency and format of meetings and communication procedures are described in further details in a DSMB Charta filed in the Trial Master File (TMF).

An emergency meeting of the DSMB may be called at any time should questions of patient safety arise and necessary safety reports will be provided. Meetings may be convened as conference calls as well as in person. Exploratory additional objectives are metagenome analysis from throat swabs and stool, viral sequencing, mucosal, humoral and cellular immune responses including single cell phenotype and RNA expression from peripheral blood cells and cytokine patterns.

The study is a randomized placebo controlled multicentric Phase II/III trial. The study scheme is shown below in Figure 1 (Frequency and Scope of the study visits). Details on the adaptive statistical design can be found in section 8.

Each patient will be given a first dose of 600 mg IMP or the equivalent number of placebo capsules (3 capsules) at the day of inclusion. From the 2 nd day on, each patient will get 200 mg or the equivalent number of placebo capsules twice a day (400mg/day) until day 7 (6 more does of 400 mg); a cumulative dose of 3 g. 

The duration of the trial for each subject is expected to be 2 months. The duration for each individual subject includes 7 days study treatment and 2 months follow-up time after randomization (see also Figure 1 ). The overall duration of the trial is expected to be approximately 8 months including preparatory phase. Recruitment of subjects will start in April 2020. The actual overall duration or recruitment may vary. The study timelines are described in Table 1 . 

The end of the study is defined as the last visit of the last patient. 

Adult male and female ≥65 years of age patients with positive COVID-19 diagnosis and fulfilling the below outlined inclusion criteria will be enrolled into the study. Trial population will consist of both genders. Gender distribution in the trial is supposed to reflect the distribution in the real patient's population, there will be no prior defined quantitative ratio between females and males.

4.1.1. Inclusion Criteria Subjects meeting all of the following criteria will be considered for admission to the trial: 

The labels for the IMP and Placebo will contain information to meet the applicable regulatory requirements. Samples of the labels have neen approved by the German Authority and are filed in the trial master file (TMF).

All trial medication must be kept in a locked area with access restricted to designated trial staff at ≤25°C. The manufacturer has no specific storage instructions.

The site investigator will keep an account of the trial medication and acknowledge the receipt of all shipments of the trial medication. Trial medication will be dispensed to the subject by the investigator. The investigator will document the date of dispensary, subject identification, batch/ serial numbers or other identification of trial medication. The investigator will also keep accurate records of the quantities of trial medication dispensed and used by each subject. Details will be recorded in the Case Report Form (CRF). The site monitor will periodically check the supplies of trial medication held by the investigator to ensure the correct accountability of all trial medication used. At the end of the trial, all unused trial medication will be destroyed by the investigator after approval of the sponsor. 

All consenting adult patients having confirmed COVID-19 will be recruited and randomly and blindly allocated in a 2:1 ratio to either IMP or placebo.

Each patient will be given a first dose of 600 mg IMP or the equivalent number of placebo capsules (3 capsules) at the day of inclusion. From the 2 nd day on, each patient will get 200 mg or the equivalent number of placebo capsules twice a day (400mg/day) until day 7 (6 more does of 400 mg).

This Study will consist of the following consecutive phases: Study entry, treatment and follow-up. Time-points and trial procedures are shown on Figure 1 .

6.1. Study Entry 6.1.1. Patient's Informed Consent The subject has to be informed both in writing and verbally by the investigator before any study-specific procedure is performed. Each patient will be informed about the modalities of the clinical study in accordance with the provided patient information. The patient is given sufficient time to consider participation in the clinical trials and ask for additional advise if needed. Informed consent from the patient will be obtained using a form approved by the responsible ethical committee (EC). The patient and informing investigator must each personally date and sign the informed consent form with an integrated declaration on data privacy protection on the same day. The original signed documents will be part of the investigator's site file and retained with it and a copy included the insurance policy of the trial will be handed to the patient. The informed consent process is documented in the patient records. Patients who fulfill all the inclusion criteria and none of the exclusion criteria will be eligible to participate in the trial. Only after the signature of the informed consent the patient will undergo study-procedures and will be randomized.

Screening and Enrollment The patients will be screened for eligibility, informed about the trial and consented for participation immediately after diagnosis of COVID-19. Next the patient will be randomized and the treatment will be allocated. For screening the following examinations are necessary:

 12 channel ECG  Baseline cardiac enzymes (CK, Troponine, BNP)  Weight, height (cm), pulse, blood pressure, body temperature (°C), respiratory rate and SpO2

 Baseline Laboratory including differential blood count, Hb, creatinine, calculated creatinine clearance, electrolytes (K, Na, Mg, Ca), glucose, troponine, CK, BNP, Bilirubine, AST, ALT, CRP, PCT, LDH, albumin, D-Dimeres, HbA1c

6.1.3. Randomisation The biostatistical center will produce a randomization list (block randomization) with varying block length and stratified for study center. This list is provided for packaging to the pharmceutical unit.

EudraCT 2020-001482-37 Date/Version19.05.2020/v3.0

Page: 27 of 53 6.1.4. Blinding IMP will be given to the patients orally. To mask the IMP versus placebo the original tablets will be encapsulated. After this step IMP and placebo will not be distinguishable. Only the pharmaceutical unit is aware of group allocation according to the randomization list. Breaking the code shall be handled conservatively and, if possible, following consultation of the investigator and the sponsor.

6.1.4.1. Unblinding Breaking the code will be done in case that patients' safety is compromised and a causal link to the IMP is suspected when allocation status is not known. This can be an emergency situation that is potentially related to IMP administration or the occurrence of an SAE where information on allocation status is important for proper clinical management. Unblinding can be considered in case of hospital admission if the above mentioned circumstances are met. The study is unblinded to clinical investigators and participants following database lock. For emergency unblinding events, a copy of sealed envelopes of the safety monitor or the delegated study team member can be used. Envelopes will be provided by the biostatistical center.

Concomitant Medication and Treatments Relevant additional medications and treatments administered to the subjects on entry to the trial or at any time during the trial are regarded as concomitant medications and treatments and must be documented on the appropriate pages of the CRF. Concomitant medication with a known risk of QT-Intervall prolongation must not be used. This includes especially antibiotics such as Macrolides or Azithromycin. Preexisting chronic medication with these drugs will not allow inclusion into the study. Information on QT-prolonging medication is available at https://crediblemeds.org/index.php/drugsearch. All patients will receive the standard of care in the participating centres. While patients will not be allowed to participate in other studies on experimental substances, it is at the discretion of the treating physician to administer any treatment that is available and he/she deems beneficial.

After randomization and treatment allocation the patients will receive the full course of the study drug or placebo. The patients will then take the first dose of the allocated treatment under observation.

Patients will be monitored via telephone or videoconference regularly. An additional monitoring will be offered via an App to prove feasibility in this study context. The app will function as a medical diary to document symptoms. Other functions especially diagnostic tests, allocation of the carrier or diagnostic analysis are not intended. Data from the app will be integrated in the study-database automatically by pseudonomized datatransfer. The patients informed consent will contain a Protocol Protocol code: COVID 65+

EudraCT 2020-001482-37 Date/Version19.05.2020/v3.0 specifically dedicated section to consent to the datatransfer. All data entered into the app is stored centrally on AWS servers in Frankfurt. The transport of data between the app and the database is encrypted with Perfect Forward Secrecy. The software libraries used are certified according to FIPS-140-2 level 1. In addition, the data stored locally on the mobile phones as well as the central database are fully encrypted.

The app does not require any permissions (except for using the camera to scan the QR code to register the study). Furthermore, no background information such as device IDs, address lists or location data is collected. Only a randomly assigned pseudonym (12 digits with mixed letters and numbers), the answers to the health questions and the ID assigned in the study are stored and transmitted. No further information is stored or processed.

Monitoring will be done on all working days and once during the weekend from day 2-7 and on day 10 (+/-2), 30 (+/-2), 60 (+/-2). Throat swabs will be performed compulsory on day 0 and 7 (+1), if feasible additionally on day 14 (+/-1) and 21 (+/-1). Clinical controls will be performed by a physician or study-nurse. Visit procedures will include symptom assessment by questionnaire and clinical examination. Blood draw for assessment of full blood count and routine clinical chemistry will be performed on days 0, 7, and according to medical necessity. ECG and measurement of cardiac enzymes will be performed day 0, and on day 7. In case of a prolongation of the QTc_time  500 ms or an increase of  60ms comparted to the value at baseline, the patient will be referred to a specialist in cardiology and will spend at least one night under observation. The cardiologist could decide that the treatment of the patient has to be unblinded.The patient continues as study patient the follow-up within the study Further samples (Throat/Buccal swabs, sputum, stool, urine, rectal swab, blood) might be collected on these days for research purposes. Blood for research purposes will be limited to 40 ml in total and will require no additional puncture but will be taken only with the planned sample. If feasible, a blood sample to determine the levels of Hydroxychloroquine will be derived on day 7 or on hospital admission to allow for assessment of dosing accuracy. In case of medical necessity of unblinding, the analysis can be initiated immediately after officially unblinding the patient. For all other cases, the blood sample will be taken and stored at -20°C. Analysis will be done at interim analysis of the subjects included or after 60 days.

Daily intake of the medication after day 0 will be done by the patient and also followed up by videoconference/phone call/App.

The efficacy will be assessed by clinical course, endpoint being rate of hospitalization or death at day 7 after study inclusion. Throat swabs will provide further information on rate of viral clearance combined with clinical assessment.

The test used to define SARS-COV-2 positivity as inclusion criterium has to be based on a dual target real time PCR assay (E/S and or R gene) and should be CE or IVD marked, but can be also for RUO (research use only) if it has a proven sensitivity to detect at least 2x10 3 copies viral RNA (LOD = level of detection) per naso-or oropharyngeal swab. Cross-reactivity to other coronaviruses besides SARS and MERS needs to be excluded. All tests must be run with a positive control and an internal control to identify possible RT-PCR inhibition and to confirm the integrity of the reagents of the test components. Diagnostic tests need to be performed in a biosafety lab level 2 and handling of the material needs to be done in a laminar flow hood by persons that wear a personaly safety equipment consisting of protective eye-wear, FFP2 masks and additional protective gowns covering the lab coat. Gloves need to be worn in a way that excludes contact of the skin with potential infectious material. Ananlysis of the results should be made by personel trained in diagnostic virology

Safety will be assessed on each visit by the study physician until the endpoint is reached and at all subsequent scheduled visits and contacts as well as at any unscheduled visit. This assessment can also be made by telephone visits, if direct contact to patient is not needed (e.g. no sampling is required).

Reasons for premature termination of trial for an individual trial subject are: 1. Death 2. Withdrawal of consent 3. Patient lost to follow-up 4. Major protocol violation 5. If, in the investigator's opinion, continuation of the trial would be detrimental to the subject's well-being 6. QTc_time prolongation > 500 ms or an increase of > 60ms comparted to the value at baseline on ECG at day 7 the patient immediately discontinues HCQ as per protocol. The patient will be referred to a specialist in cardiology and will spend at least one night under observation. The cardiologist could decide that the treatment of the patient has to be unblinded. The patient continues as study patient the follow-up within the study 7. Noncompliance The investigator decides about withdrawal of subjects from trial treatment in case of occurrence of criteria mentioned above. In all cases, the reason for withdrawal must be recorded in the CRF and in the subject's medical records. In case of withdrawal of a subject at his/ her own request, the reason should be determined and documented.

All examinations scheduled for the last trial day will be performed and documented as far as possible, subject to the consent of the patient. These subjects will enter the regular follow-up of the trial, unless the subject has withdrawn his/her consent to any further study-related procedure. If a subject may / will be withdrawn from all trialrelated procedures (including follow-up visits) (e.g. at his/her own request), this will not result in any disadvantages for the patient. All ongoing Adverse Events (AEs)/ Serious Adverse Events (SAEs) of withdrawn subjects have to be followed-up until no more signs and symptoms are verifiable or the subject is on stable condition.

Premature termination should be avoided. In case of a premature termination of therapy, reasons/circumstances and if applicable the final status have to be documented. If the patient does not withdraw the consent for further follow-up, he/she should be followed-up as planned.

6.6. Premature closure of a trial site Premature closure of a trial site has to be considered if:  The conduct of the study is not compliant with the protocol or the legal regulations, or  The data quality is not sufficient

The premature closure of a site will be decided by the sponsor. Site principal investigators may terminate his/her participation in the study. If this occurs they should provide a written statement of the reasons for terminating participation and should provide the sponsor with all available and up-to-date study data.

The sponsor may also decide to terminate participation of an investigator or study center for the following reasons:  Breach of agreement  Serious non-compliance to protocol or the legal regulations  Insufficient patient recruitment If a participating center closes, or is closed, prior to termination of the whole trial, the sponsor expects that data from patients already entered into the trial will be reported as per protocol. Details on further treatment and follow-up of patients on study have to be discussed with the site principal investigator.

The trial may be prematurely terminated, if in the opinion of the sponsor and coordinating investigator there is sufficient reasonable cause. Written notification documenting the reason for study termination will be provided to the investigators. In case of the following situations, a premature termination of the trial has to be considered:

 Serious adverse drug reactions / not justifiable toxicity  Substantial changes in risk-benefit considerations  New insights from other trials  Insufficient efficacy  Insufficient recruitment rate

The DSMB will monitor the study conduct and the safety aspects of the trial on a regular basis, and will give recommendations to the coordinating investigator/ the sponsor whether to stop the trial or to change the trial protocol. The sponsor will then decide on the actions to be taken. According to the German Medicinal Products Act ( §42a), the trial may be suspended or prematurely terminated by decision of the competent authority (BfArM).

The patients will be followed up until 2 months after randomization. During this time safety assessment will be performed and at all follow up visits samples will be collected of exploratory endpoints analysis.

The end of Study for a subject enrolled in this trial is defined as the last study visit.

(Last Follow-up visit).

6.9.1. Plan for Treatment or Care after End of Study After end of the Study for a subject enrolled in this trial no additional treatment or care is required except for normal routine care.

7. Quality control and Quality assurance 7.1. Risk-based approach During protocol development, processes and data that are critical to ensure human subject protection and the reliability of trial results were identified.

The identified risks were evaluated against existing risk controls by considering:

 The likelihood of errors occurring  The extent to which such errors would be detectable  The impact of such errors on human subject protection and reliability of trial results.

In case of unacceptable risks, risk reduction activities were defined and incorporated e.g. in the protocol, monitoring plan and agreements.

Results will be communicated to those who are involved in or affected by such activities.

The sponsor periodically reviews risk control measures to ascertain whether the implemented activities remain effective and relevant, considering emerging knowledge and experience.

Monitoring for this study is provided by the Zentrum für Klinische Studien Tübingen (ZKS Tübingen). The monitoring will be conducted according to ZKS Tübingen internal Standard Operating Procedures (SOPs) and a dedicated monitoring manual for the study. The monitoring timelines include, for all centres, initiation visit, regular monitor visits during the course of the trial as well as a close out visit. Usually, Monitoring will end with the last visit after full documentation of the last patient enrolled (close out visit). All investigators agree that the monitors regularly visit the trial site, assure that the monitors will receive appropriate support in their activities and will have access to all trial-related documents. The aims of the monitoring visits are as follows:  Check informed consent documents  Monitor trial subject safety (occurrence and documentation/reporting of Serious Adverse Events (SAEs) and Adverse Events (AEs)).  Check completeness and accuracy of entries on the CRFs.  Validate entries on the CRFs against those in the source documents (source data verification (SDV)).  Check the Drug Account  Evaluate compliance with the trial protocol  Assess whether the trial is being performed according to GCP at the trial site  Discuss with the investigator aspects of trial conduct and any deficiencies found  A monitoring visit report is prepared for each visit describing the progress of the clinical trial and any problems

In addition to the monitoring activities, audits can be conducted by the sponsor or assigned auditors. These audits may include checking the whole course of the study, documentation, trial centre, investigators and the monitor.

The competent regulatory authorities may also conduct inspections.

With his/her participation in the study, the investigator agrees to support the activities of the auditor/inspector, provide her/him with direct access to the source documents, study documentation and give her/him the opportunity to audit/inspect the study site, laboratory facilities, storage of the investigational product, etc.

The trial Case Report Form (CRF) is the primary data collection instrument for the trial. All data requested on the CRF must be recorded. All missing data must be explained.

For this project, electronic Case Report Forms (eCRFs) will be used.

The correctness of entries in CRFs will be confirmed by of an authorized investigator. The investigator is responsible for ensuring that all sections of the CRF are completed correctly and that entries can be verified against source data. The investigator has to verify the eCRFs via electronic signature after completion of the CRFs.

Source Data Source data is all information, original records of clinical findings, observations or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents. Examples of these original documents and data records include: hospital records, clinical and office charts, laboratory notes, memoranda, patients' diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, x-rays, CTs, MRIs, ultrasound reports, patient files, and records kept at the pharmacy, at the laboratories, and at medico-technical departments involved in the clinical trial.

Data Handling Data will be entered in a validated GCP conform database or in a paper-based CRF until the database is available. After completion of data entry, checks for plausibility, consistency, and completeness of the data will be performed. Based on these checks, queries will be produced.

Storage and Archiving of Data According to the EU Clinical Trial Regulation 536/2014 all essential trial documents (e.g. CRF) will be archived for at least 25 years after the trial termination. The investigator(s) will archive all trial data (source data and Investigator Site File (ISF) including subject identification list and relevant correspondence) according to the Guideline ICH GCP (E6).

Before unblinding of the trial, a statistical analysis plan (SAP) will detail the analysis of the trial.

Details of participants screened meeting the study inclusion criteria and participating baseline visit, those who are eligible and randomized, those who are eligible but not randomized, those who withdraw from the study after randomization and those who are lost to follow-up will be summarized in CONSORT flow diagrams. The number of participants discontinuing from the study will be tabulated by reason for study discontinuation. The number (%) of participants attending scheduled followup visits will be reported. The baseline value is defined as the last available value before randomization. Once enrolled, all participants are randomized into two treatment groups. Participants in each group will be described with respect to demographic and baseline characteristics. Intention to Treat (ITT) population: all recruited participants that received at least one dose of the study drug. Per Protocol (PP) population: all participants having received a full course of the study medication and not withdrawn due to protocol violations until the respective follow-up duration.

From data presented by the CDC (MMWR 2020) for march 12 th until march 16 th hospitalization rates in the USA were between 28.6% and 43.5%% in the age group between 65-74 ys and between 30.5% and 58.7% in the age group of 75-84 ys. We have to expect considerably smaller rates in our study population, without clear prior evidence. Thus, as a primary guess, we assume a hospitalization rate of 25% in the Placebo group. Taking into account possible adverse drug reactions in the group with Hydroxychloroquine a relevant absolute risk reduction of 15% (number needed to treat: 7) in this group would lead to a hospitalization rate of 10%. In a fixed sample size design and taking into account the 2:1 relation of Chloroquine vs. Placebo a total of 213 evaluable patients (142 vs. 71) would be necessary to achieve a power of 80%, and a total of 291 (194 vs. 97) evaluable patients would be necessary to achieve a power of 90%: Taking into account the short time interval of seven days between randomization and assessment of the primary endpoint, a drop out rate of at most 10% seems to be realistic. Thus, to achieve a power of 80%, 237 patients should be recruited, for a power of 90%, 324 patients have to be recruited. We chose the power of 90% and thus the fixed sample size would be n=326 patients (including one degree of freedom for center effects). Note, however, that we will use an adaptive design which will enable us to adjust the sample size after an interim analysis (see below).

In view of the weak evidence of the Placebo and Verum hospitalization rates, and the short time from randomization to the assessment of the primary endpoint, an adaptive design is adequate. The primary endpoint will be analysed in Step 1 if 108 patients (72 vs. 36) with primary endpoint are observed. However, all subjects with baseline information will be included according to the intention-to-treat principle. The interim analyses will be conducted by a statistician not involved in the design and analysis of this trial to preserve blinding of the study statistician. Based on the pvalue p 1 of this stage and the observed effect, the statistical planning of the second stage, including the p-value p 2 necessary to obtain an overall significant result will be performed. The analysis will be done for α 0 = 0.4 (stopping for futility after stage 1), α 1 = 0.0115 (stopping for success after stage 1), and c α = 0.00380 (critical value of the product p 1 times p 2 after stage 2) for a one-sided overall α of 0.025 in the terminology of Bauer and Köhne (1994) . This leads to p-values of 0.0115 in the first stage and 0.00380/p1 in the second stage necessary to get a significant overall result. The sample size of 108 patients with primary outcome available in stage one leads to the following probabilities: If we assume a true effect of 0.25 vs. 0.10, the power to proceed to the second stage or stop early for success is 0.98. In case of a true effect of 0.20 vs. 0.10 the power is still 0.90. The power for early stopping for success (which is not intended in this situation) is 0.42 (0.25 vs. 0.10) and 0.22 (=.20 vs. 0.10). If we reversely assume, that there is a harm of Chloroquine of 25% vs. 10% (20% vs. 10%) hospitalization, the probability to erroneously proceed to stage 2 is less than 1% (5%).

Statistical analysis of the primary outcome will be a chi-square test stratified for study center (Mantel Haenszel) with type 1 error 0.025 (one-sided). This will be done identical in stage 1 and stage 2 of the adaptive design. One-sided p-values can be obtained by using the signed square root of the chi-square value.

In secondary analyses of the primary enpoint, multiple logistic regression models will be used by including terms for age, gender, duration of symptoms, and baseline virus load as covariates additional to study arm and treatment center. No subgroup analyses are planned, however, if significant interactions between one of these variables and the treatment arm are observed, effect modification will be assessed by chosing two subgroups, using the median in case of continuous covariates.

Analysis of secondary outcomes will be done according to scaling and observed distributions of the data. Concretely, the following methods will be applied:

• Duration of hospitalization (median, quartiles, Mann-Whitney test)

• Time to hospitalization (90%, 75%,median time, Kaplan-Meier method with log rank test) • Reason for hospitalization (95% confidence limits of rates and their differences, Chi-Square test and) • Severity of disease at hospitalization (median, quartiles, Mann-Whitney test)  All-cause mortality within 30/60 days (99%, 95%, 90%, Kaplan-Meier method with log rank test) • COVID19 related mortality within 30/60 days (99%, 95%, 90%, Kaplan-Meier method with log rank test) • Proportion requiring invasive ventilation (95% confidence limits of rates and their differences, Chi-Square test) • Proportion admitted to ICU (95% confidence limits of rates and their differences, Chi-Square test) • Rate of viral clearance defined as SARS-CoV2 specific RNA copy number <100 in throat swabs on day 7 (95% confidence limits of rates and their differences, Chi-Square test) • Optional rate of viral clearance on d 14, 21 (95% confidence limits of rates and their differences, Chi-Square test) Even so p-values will be reported, the analyses should be considered non confirmatory. Additional exploratory analyses might be performed using adequate multiple regression models (linear, logistic, Cox proportional hazard model).

The primary analysis population is the intent to treat population. Only patients with baseline assessment will be included in this population to make imputation of missing values for the outcome feasible.

We will use a multiple imputation approach for drop outs using the baseline data. These will include age, gender, duration of symptoms as well as virus load at baseline. Dependent on the observed missing pattern, data after baseline and before day seven might be included in the imputation model. Data are assumed as missing at random (MAR). A monotone pattern over time will be used, if data fit to this assumption.

The following summary statistics on AEs will be presented by treatment group:

 Number and percentage of participants with any AE during the study period  Number and percentage of participants with any SAE during the study period  Number and percentage of AEs which caused early discontinuation of the investigational medical product (IMP)

All participants in the treatment group are considered in the denominator unless otherwise specified. A descriptive overview of all AEs will be reported cumulatively. In addition, AEs will be reported, only considering the most severe event for all participants with multiple occurrences of events. In the final report a full listing of AEs will be provided.

See section adaptive designs. Additionally, a safety monitoring of 20 patients in the verum group will be performed not embedded in the framework of the adaptive design according to Bauer and Köhne (1994) 9. Safety 9.1. Definition of Adverse Events and Side Effects 9.1.1. Adverse Events Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An AE may be:

 New symptoms/ medical conditions  New diagnosis  Changes of laboratory parameters  Diseases and medical consequences of an accident  Worsening of medical conditions/ diseases existing before clinical trial start  Recurrence of disease  Increase of frequency or intensity of episodical diseases A pre-existing disease or symptom will not be considered an adverse event unless there will be an untoward change in its intensity, frequency or quality. This change will be documented by the investigator.

In general, abnormal laboratory findings or clinical events without clinical significance (based on the investigator´s judgement) should not be recorded as AEs.

Surgical procedures themselves are not AEs; they are therapeutic measures for conditions that require surgery. The condition for which the surgery is required may be an AE. Planned surgical measures permitted by the clinical trial protocol and the condition(s) leading to these measures are not AEs, if the condition leading to the measure was present prior to inclusion into the trial.

AEs are classified as "non-serious" or "serious".

Adverse Drug Reaction Adverse reaction means all untoward and unintended responses to an investigational medicinal product unrelated to the dose administered.

Unexpected Adverse Drug Reaction An unexpected Adverse Drug Reaction (ADR) is a reaction which nature or severity is not consistent with the applicable product information available for the IMP. Expected ADRs are listed in the appropriate reference document: Summary of Product Characteristics (SmPC [Fachinformation in Germany]).

Serious Adverse Event and Serous Adverse Reaction AEs are classified as "non-serious" or "serious".

A serious adverse event (SAE) is one that at any dose:

 Results in death.  Is life-threatening (the term life-threatening refers to an event in which the subject was at risk of death at the time of event and not to an event which hypothetically might have cause death if it was more severe).  Requires subject hospitalization or prolongation of existing hospitalization.  Results in persistent or significant disability/ incapacity.  A congenital anomaly / birth defect.

In this Study the following events have to be reported as SAE  any arrhythmia that needs treatment  any life threatening cardiac conduction disorder

For the purpose of this trial, the period of observation for collection of adverse events for each patient goes from the time of first administration of the IMP until 30 days after first dose. AEs will be elicited at all follow up visits as well. SAE will be documented during the whole trial period. All adverse events that occur in the course of a clinical trial regardless of the causal relationship must be monitored and followed up until the outcome is known or no more information is achievable.

9.3.1. Documentation and Reporting of Adverse Events by the Investigator The investigator must document all adverse events that occur during the observation period set in this protocol on the pages provided in the case report form. Additional instructions may be provided in the investigator file and in the case report form itself. The following approach will be taken for documentation: All adverse events (whether serious or non-serious) must be documented on the "adverse event" page of the case report form. If the adverse event is serious, the investigator must complete, in addition to the "adverse event" page in the case report form, a "serious adverse event report form" at the time when the serious adverse event is detected. The investigator will document the date when he/she or any employee was first aware of the report and fax all SAE reports (initial and follow-up reports), even if they are incomplete, directly or latest 24 hours upon receipt to the representative of the Sponsor:

Fax +49 7071 29 25205 E-mail: zks-pv@med.uni-tuebingen.de

The investigator should also assess the severity and the causal relationship between the event and the trial medication.

Assessment of Severity and Causality The investigator will also provide an assessment of the severity of the event according to CTCAE criteria (Version 5.0) and causal relationship between the event and each of the investigational products or trial procedures. AEs and SAEs should be evaluated for severity according to the following scale:

 Grade 1 -mild event: Causing no limitations of usual activities; the patient may experience slight discomfort.  Grade 2 -moderate event: Causing some limitation of usual activities; the patient may experience annoying discomfort.  Grade 3 -severe event: Causing inability to carry out usual activities; the patient may experience intolerable discomfort or pain.

 Grade 4 -life threatening or disabling event  Grade 5 -death related to event

The investigator should also assess the causal relationship between the event and the trial medication to following scale: Is there a reasonable causal relationship that the AE is related to the study medication? Y (Yes) There is a reasonable possibility that the IMP/s caused the AE. N (No) There is no reasonable possibility that the IMP/s caused the AE and other causes are more probable. If no, other possible causes have to be specified.

The information about the outcome of an AE at the time of the last observation should also be reported. The following classification will apply: Recovered/ Resolved:

All signs and symptoms of an AE disappeared without any sequels at the time of the last interrogation.

Recovering/ resolving:

The intensity of signs and symptoms has been diminishing and/ or their clinical pattern has been changing up to the time of the last interrogation in a way typical for its resolution.

Not recovered/ not resolved:

Signs and symptoms of an AE are mostly unchanged at the time of the last interrogation.

Recovered/ resolved with sequel:

Actual signs and symptoms of an AE disappeared but there are sequels related to the AE.

Resulting in death. If there are more than one AE only the adverse event leading to death (possibly related) will be characterized as 'fatal'.

The outcome is unknown or implausible and the information cannot be supplemented or verified.

9.3.4. Sponsors Assessment of the SAEs All SAE will be subject to a second assessment by the trial Sponsor or authorized second assessors.

The second assessor will fill out a 'Second Assessment Form' for each SAE containing.

 Event serious yes/no  Relationship between SAE and IMP  Expectedness of SAE according to the reference document: SmPC of Hydroxychloroquine.

 Benefit / risk assessment for the trial regarding change as a result of SAE.

EudraCT 2020-001482-37 Date/Version19.05.2020/v3.0 Page: 43 of 53 9.3.5. Follow-up of Initial Report Information not available at the time of the initial report (e.g. end date for the adverse event or laboratory values received after the report) must be documented on a "Serious Adverse Event" form with the box "Follow-up" checked under "Report type". All patients who have adverse events, whether considered associated with the use of the investigational products or not, must be monitored to determine the outcome as far as possible. The clinical course of the adverse event will be followed up according to accepted standards of medical practice even after the end of the period of observation, until a satisfactory explanation is found or the investigator considers it medically justifiable to terminate follow-up. Should the adverse event result in death, a full pathologist's report should be supplied, if possible. The sponsor will identify missing information for each SAE report and will require follow up information in regular intervals from the investigators until all queries are resolved or no further information can be reasonably expected. All responses to queries and supply of additional information by the investigator should follow the same reporting route and timelines as the initial report.

Suspected Unexpected Serious Adverse Reaction (SUSAR) SAEs have to be assessed by the second assessor whether they are both suspected, i.e. related to IMP and 'unexpected', i.e. the nature and / or severity of which is not consistent with the applicable product information. They are then to be classified as Suspected Unexpected Serious Adverse Reactions (SUSARs). In case, either the investigator or the second assessor classifies the SAE as related to IMP and the SAE is unexpected as assessed by the second assessor it will be categorized as a SUSAR. All SUSARs are subject to an expedited reporting to the responsible ethics committee(s), the competent higher federal authority (i.e. BfArM) and to all participating investigators.

Expedited Reporting to the Regulatory Authorities In this study any death, any arrhythmia that needs treatment and any life threatening cardiac conduct disorder must be evaluated by the DSMB and are subjected to expedite reporting to the authority and the ethic-commission.

The competent authority and the ethics committee responsible must be informed by the Sponsor of all fatal or life-threatening SUSARs. This must be done immediately, at the latest seven calendar days after becoming aware of the minimum criteria for reporting. In all cases, attempts must be made to obtain further relevant information, which must be supplied to the competent authority and the ethics committee in overall charge within a further eight days. Furthermore, if a trial subject dies, this information must be additionally passed on to the ethics committee responsible for the region in which the death occurred.

The authority and the ethics committee responsible will be informed without delay by the sponsor or CI of all SUSARs, at the latest within 15 calendar days of becoming aware of the minimum criteria for reporting. Further relevant details will be passed on as soon as possible. If the information at the time of reporting is incomplete, further information to enable adequate assessment of the case will be requested from the reporter or other available sources.

Unblinding of the Medical Product If it is medically imperative to know which trial medication the subject is receiving, the investigator or authorized person should open the randomization envelope. The investigator or the person who breaks the blind must record the date and the reasons for unblinding in the CRF, in the subject's medical record and on the randomization envelope. Whenever possible, the Sponsor / CI should be contacted before the blind is broken.

Examination and Report of Changes in the Risk to Benefit Ratio Without delay, and at the latest within 15 days of the decision for the need to do so, the Sponsor / CI will inform the competent authority, the ethics committee responsible of any events or factors that could result in a review of the risk-benefit ratio of the IMP. These consist of especially:

 Individual reports of expected serious ADRs with an unexpected outcome.  A clinically relevant increase in the rate of occurrence of expected ADRs.  SUSARs in trial subjects who have already completed the follow-up period of the clinical trial ("end-of-trial visit"). 

Factors emerging in connection with trial conduct or the development of the IMP that may affect the safety of persons concerned.

9.3.10. Reporting to Data and Safety Monitoring Board In this study any death, any arrhythmia that needs treatment and any life threatening cardiac conduct disorder must be evaluated by the DSMB and are subjected to expedite reporting to the authority and the ethic-commission. The DSMB will be informed of all safety-relevant events by the Sponsor. The frequency of reporting will be described in the DSMB chapter.

9.3.11. Report to the Investigator The Sponsor will inform investigators of all SUSARs including all relevant further information within the periods set by the authority. If new information becomes known that is different from the scientific information given to the investigator, all investigators will be informed of this by the sponsor.

Once a year, the Sponsor will supply a report on the safety of trial subjects with all available relevant information concerning patient safety during the reference period to the competent authorities. This report will also be supplied to the responsible ethics committee. The annual safety report will be compiled according to the corresponding ICH guideline E2F "Development Safety Update Report -DSUR". The safety report will cover all IMPs used in this study.

The procedures set out in this trial protocol, pertaining to the conduct, evaluation, and documentation of this trial, are designed to ensure that all persons involved in the trial act according to Good Clinical Practice (GCP) and the ethical principles described in the applicable version of the Declaration of Helsinki.

Clinical Trial in accordance with the German Medicinal Products Act (Arzneimittelgesetz, AMG).

Each patient will be informed about the modalities of the clinical study in accordance with the provided patient informed consent (IC). The patient is to be informed both in writing and verbally by the investigator before any study-specific procedure is performed. The patient must be given sufficient time to decide whether to participate in this comparative study and to ask questions concerning this trial. It must also be made clear to the patient that he / she can withdraw from the study at any time without giving reasons and that he / she will not be in any way disadvantaged for this. The subject must give consent in writing. The patient and informing physician must each personally date and sign the informed consent form with an integrated declaration on data privacy protection, whereby the physician must not sign before the patient. Original signed documents will be part of the investigator's file and retained with it. A copy of the signed informed consent document and study insurance policy must be given to the subject. The documents must be in a language understandable to the subject and must specify who informed the subject. The subjects will be informed as soon as possible if new information may influence his/her decision to participate in the trial. The communication of this information should be documented in the patient chart.

Each patient is insured against any health impairment occurring as a result of participation in the study in accordance with the laws and regulations of the "German Arzneimittelgesetz". The insurance is covered by HDI-Gerling Industrie Versicherung AG, Am Schönenkamp 45, 40599 Düsseldorf, Policy number 57 010311 03013/03052 and valid throughout the conduct of the study for each individual patient. A copy of the insurance policy and conditions are distributed to the patient upon enrollment into the study and the patient is advised to adhere to the conditions of the insurance policy to safeguard a valid patient insurance. Further the insurance cover exists for accidents of the patients enrolled to the Study:  on the direct route from home, workplace or school to the place of study;  on the direct route from the place of study back to one of these places and  during the stay at the place of study from the time you enter the place of study until you leave. The insurance cover does not apply if the normal duration of the journey is extended or the journey itself is interrupted by purely private measures. During the stay at the place of study, no insurance cover exists for the duration of the examination or treatment within the scope of the study, provided that claims can be asserted under the probationer insurance.

The data obtained in the course of the trial will be treated according to the European General Data Protection Regulation (Datenschutz-Grundverordnung; DS-GVO) and the applicable local data protection regulations as well as the AMG.

Subjects have to be informed about data protection in the clinical trial and to consent in writing to collect and process their personalized data as well as to transfer their pseudonymized data. The information has to be transparent, precise, easily accessible and understandable and is written in clear and simple language. The written privacy policy must be approved by the responsible ethics committee.

In order to maintain patient privacy, all data capture records, study drug accountability records, study reports and communications will identify the patient by the assigned patient number. The PI determines which persons are authorized to view personal data, the Patient Identification Log is only accessible to authorized study team members. Access rights to personal data (including pseudonymized data) are available to prevent unauthorized access to the data (both electronically and physically). Electronic systems and files are access-regulated, possibly passwordprotected. Documents and files are kept in lockable rooms, if necessary, cupboards with access control.

The patient name, initials and the full birth date should never be used in any correspondence with the Sponsor or on the Case Report Forms. The investigator will grant monitor(s) and auditor(s) and/or regulatory authorities direct access to the patient's original medical records for verification of data gathered on the data capture records and to audit the data collection process. Direct access includes examining, analyzing, and verifying any recorded data and reports that are important to the evaluation of the monitoring. The investigator is obliged to inform the patient that his/her trial-related records will be viewed without violating their confidentiality and that the collected information will only be made publicly available to the extent permitted by the applicable laws and regulations. All data will be stored either paper based or electronically in a pseudonymous manner and handled strictly confidential. The investigators are obliged to keep all study data and information confidential and to use those data only in context with the persons involved in the trial conduct. Study material or information developed in this trial must not be available to third parties, except for official representatives of the sponsor or regulatory authorities. Data will be processed at the study site according to the written safety concept of this institution. Access to the data will be strictly limited to authorized persons. Loss of data is excluded due to extensive back-up procedures. All legal requirements concerning data protection and confidentiality will be respected. All authorized persons are sworn to secrecy. In the case of withdrawal of consent the stored data collected to this time point will be stored and further used. Data not necessary any longer are deleted immediately. Collected study data will be stored for at least 25 years after the end of the trial, if there are no other regulatory archiving periods. After archiving has expired, the data will be destructed in a data protection compliant manner.

When processing personal data, the following principles must be observed (pursuant to DS-GVO Article 5 "Principles relating to processing of personal data"):

Personal data shall be: o processed lawfully, fairly and in a transparent manner in relation to the data subject o collected for specified, explicit and legitimate purposes and not further processed in a manner that is incompatible with those purposes o adequate, relevant and limited to what is necessary in relation to the purposes for which they are processed o accurate and, where necessary, kept up to date o kept in a form which permits identification of data subjects for no longer than is necessary for the purposes for which the personal data are processed o processed in a manner that ensures appropriate security of the personal data, including protection against unauthorized or unlawful processing and against accidental loss, destruction or damage, using appropriate technical or organizational measures

The investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, any amendments to the protocol, the trial treatments, and their trial-related duties and functions. The investigator should maintain a list of sub investigators and other appropriately qualified persons to whom he or she has delegated significant trial-related duties.

Prior to the beginning of the clinical phase (First Patient In) the Sponsor will register the trial in the EudraCT as well as ClinicalTrials.gov Database.

Within one year of the completion of the trial, the competent authority and the ethics committee will be supplied with a summary of the final report on the clinical trial containing the principle results. All reports to the sponsor will be written in English language. All clinical, analytical and statistical results will be presented in a final clinical trial report (CTR). The outline of this report will accord to the ICH Topic E3.

The final results of this study will be presented at scientific meetings and published in a peer reviewed leading medical journal of infectious disease medicine or a leading clinical journal. All publications in result of this study are the responsibility of the principal coordinating investigator and the authorship will reflect the contributions of each collaborating centre. Any publication, abstract or presentation based on patients included in this study must be approved by the coordinating investigator.

COVID 65+ EudraCT

Protocol Protocol code: COVID 65+ EudraCT

Protocol Protocol code: COVID 65+ EudraCT

Muster-Prüfpaln_Version v6-03-F" Grass and Weiß Medicinal Products Act (Arzneimittelgesetz)

2757) Ordinance on the implementation of Good Clinical Practice in the conduct of clinical trials on medicinal products for use in humans (GCP Ordinance -GCP-V)

Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95)

Clinical Trial Facilitation Group, Recommendations related to contraception and pregnancy testing in clinical trials

On Data Monitoring Committees (EMEA/CHMP/EWP/5872/03 Corr)

on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation)

Evaluation of experiments with adaptive interim analyses

COVID19 / SARS-CoV2 -related References in order of citation

Clinical management of severe acute respiratory infection when Novel coronavirus

According to the German Drug Law (AMG) and the GCP Ordinance, the EC and the competent authority will be informed of all suspected serious unexpected adverse reactions (SUSARs). Both institutions will be informed in case the risk/ benefit assessment did change or any others new and significant hazards for subjects' safety or welfare did occur. Furthermore, a report on all observed SAEs will be submitted once a year -Annual Safety Report. The EC and the regulatory authorities must be informed of the end of the trial. They will be provided with a summary of trial results within one year after the end of clinical phase.

Before the start of the trial, the trial protocol, informed consent document, and any other appropriate documents will be submitted to the independent Ethics Committee (EC) as well as to the competent authority (BfArM). A written favourable vote of the EC and an (implicit) approval by the competent higher federal authority as well as the notification of the local authorities (acc. to §67 AMG) are a prerequisite for initiation of this clinical trial. Before the first subject is enrolled in the trial, all ethical and legal requirements must be met. All planned substantial changes (see §10, (1) of German GCP-Regulation) will be submitted for approval to EC and the competent authority in writing as protocol amendments.

EudraCT 2020-001482-37 Date/Version19.05.2020/v3.0